The major advantage of Western blot analysis with p-ERK1/2 antibodies is the possibility to differentiate between both activated kinases (p-ERK1 and p-ERK2), whereas its major drawback is the failure to discriminate between protein expression in tumour cells and accompanying nonmalignant cell types. This evidence concerns the gene MAPK3 and neoplasm.